Emilia Javorsky
speaker
1,653 appearances
2 recordings
1 series
first heard Mar 2026
last heard 20 Mar
Emilia Javorsky’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Mar 2026 with 2.
Appearances
A plan with the scale, coordination, and resolve to end it.
Major tech companies are racing to create Artificial Superintelligence, ASI.
Current artificial intelligence already operates beyond human capabilities in specific domains with well-defined boundaries such as in chess or image classification.
By contrast, superintelligence would be AI that substantially exceeds human cognitive capability across the vast majority of domains.
Tech companies have pitched superintelligence as the answer, making cancer cures their flagship promise.
The pitch is seductive, summoning superintelligent AI genies to grant unlimited wishes like
unimaginable economic growth, breakthrough treatments for devastating diseases, and reversing climate change.
Think of the children, they implore, pulling heartstrings by invoking illness, suffering, and hope.
Curing cancer is a big promise, and one that is universally considered one of the most noble and good things we can fund.
But rarely is the substance of their promises examined.
The logic appears airtight.
If we can create systems of superior intelligence to humans across all domains, surely they will solve what has eluded our brightest scientists for decades.
In 2024, Anthropic CEO Dario Amode suggested that AI-enabled biology and medicine will allow us to compress the progress that human biologists would have achieved over the next 50 to 100 years into 5 to 10 years, calling this the compressed 21st century.
The potential for infinite benefit, we're told, justifies near infinite risks and infinite investment.
Any regulatory or resource constraint that might slow this race becomes unconscionable when cancer cures hang in the balance.
This approach makes a dangerous assumption that insufficient intelligence is the primary barrier to new cancer therapies.
Somehow, raw computational power alone is the thing that can overcome the complex landscape of data gaps, biological complexity, regulatory constraints, and misaligned incentives that have caused billions in previous healthcare investments to fail.
In fact, exponential growth in biomedical knowledge is already here.
The doubling rate of medical knowledge was 50 years in the 1950s and, by some estimates, was down to every 73 days by 2020.
Yet this intelligence explosion has not significantly moved the needle on cancer mortality.
Showing 661–680 of 1,653 · page 34 of 83
← Previous
Next →